These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1280 related items for PubMed ID: 11240980

  • 1. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
    Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E.
    Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
    [Abstract] [Full Text] [Related]

  • 2. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T.
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [Abstract] [Full Text] [Related]

  • 3. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T.
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [Abstract] [Full Text] [Related]

  • 4. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T, Shirai N, Xiao F, Takashita M, Sugimoto M, Kajimura M, Ohashi K, Ishizaki T.
    Hepatogastroenterology; 2003 Jul; 50(54):2274-8. PubMed ID: 14696516
    [Abstract] [Full Text] [Related]

  • 5. Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
    Furuta T, Sugimoto M, Shirai N, Matsushita F, Nakajima H, Kumagai J, Senoo K, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Umemura K, Ishizaki T, Hishida A.
    Aliment Pharmacol Ther; 2007 Sep 01; 26(5):693-703. PubMed ID: 17697203
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
    Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, Shiratori Y.
    Am J Gastroenterol; 2003 Nov 01; 98(11):2403-8. PubMed ID: 14638340
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
    Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K.
    Clin Gastroenterol Hepatol; 2004 Jan 01; 2(1):22-30. PubMed ID: 15017629
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K, Sugiyama T, Kato M, Saito M, Miyagishima T, Kudo M, Nishikawa K, Ishizuka J, Komatsu Y, Mizushima T, Kagaya H, Hige S, Takeda H, Asaka M.
    Aliment Pharmacol Ther; 2001 Sep 01; 15(9):1479-84. PubMed ID: 11552922
    [Abstract] [Full Text] [Related]

  • 14. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M.
    Eur J Clin Pharmacol; 2005 Jul 01; 61(5-6):375-9. PubMed ID: 15976989
    [Abstract] [Full Text] [Related]

  • 15. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
    Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH.
    Pharmacotherapy; 2011 Mar 01; 31(3):227-38. PubMed ID: 21361732
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX, Zhao YH, Hao YT.
    Zhonghua Nei Ke Za Zhi; 2004 Jan 01; 43(1):13-5. PubMed ID: 14990013
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.